MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Cardiovascular Systems prices $33M offering | Wall Street Beat

Cardiovascular Systems prices $33M offering | Wall Street Beat

By

MassDevice.com Wall Street Beat

Cardiovascular Systems (NSDQ:CSII) priced a public offering of some 2 million shares of CSII stock at $17.60 apiece, saying it expects to net about $33 million from the deal.

The St. Paul, Minn.-based medical device company has said it plans to use the proceeds for working capital and general corporate purposes, which is likely to include backing for its ORBIT II clinical trial of its atherectomy device.

CSII shares jumped nearly 18% last week after the company revealed what 1 analyst called "convincingly positive" 30-day data from the ORBIT II study.

Sign up to get our free newsletters delivered straight to your inbox

The offering includes a 30-day over-allotment option of 300,000 shares for the underwriters, according to a press release.

CSII shares were trading at $18.62 each as of about 12:50 p.m. today, up 4.8%.

 Sleep coach Zeo Inc. to shut down?
Newton, Massachusetts-based sleep monitoring and coaching company Zeo is closing up shop and seeking a buyer, according to mobihealthnews.
Read more

 Imaging Acquisition picks up LumeGEM molecular breast imaging biz out of bankruptcy
Psilos Group’s Imaging Acquisition Inc. said it’s acquired the LumaGEM molecular breast imaging business of Gamma Medica Inc. in a Chapter 11 bankruptcy sale.
Read more

 Kips Bay regains NASDAQ’s good graces
Kips Bay Medical (NSDQ:KIPS) said it’s back in the NASDAQ stock exchange’s good graces now that its share price has been above $1 apiece for 10 consecutive business days. The exchange warning the company last month of a possible delisting if it couldn’t get its share price above the $1 minimum requirement.
Read more

 US HIFU changes name to SonaCare Medical
US HIFU LLC said it’s changed its name to SonaCare Medical "to better align with our strategic vision of expanding our current HIFU technology to treat a range of urological indications," according to CEO Michael Klein.
Read more

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): Deutsche Bank maintains “hold” rating.
  • Cardinal Health (NYSE:CAH): Goldman Sachs reiterates "neutral" rating, lowers price target from $50 to $48; ISI Group downgrades from "strong buy" to "buy" rating, lowers price target from $50.50 to $48.50; Morgan Stanley reiterates "overweight" rating, lowers price target from $54 to $48.
  • Delcath (NSDQ:DCTH): Wedbush maintains "outperform" rating, lowers price target from $9.55 to $5.
  • Echo Therapeutics (NSDQ:ECTE): LifeTech Capital reiterates "strong speculative buy" rating, lowers price target from $5 to $3.75.
  • Endo Health (NSDQ:ENDP): Bank of America reiterates $33 price target, “buy” rating.
  • ICU Medical (NSDQ:ICUI): Benchmark Co. reiterates "buy" rating, $69 price target.
  • Intuitive Surgical (NSDQ:ISRG): Lazard maintains "buy" rating, $625 price target.
  • McKesson (NYSE:MCK): Goldman Sachs reiterates "buy" rating, lowers price target from $124 to $122.
  • NuVasive Inc. (NSDQ:NUVA): TheStreet upgrades from "sell" to "hold" rating.
  • Opko (NYSE:OPK): Jefferies reiterates "buy" rating, raises price target from $8 to $9.
  • Optos plc (LON:OPTS): Singer cuts Optos to "sell" to "hold" rating, maintains 172p price target.
  • Smith & Nephew (FTSE:SN, NYSE:SNN): Morgan Stanley raises price target from $10.39 to $10.98, maintains “equal weight” rating.
  • Steris (NYSE:STE): Bank of America reiterates "buy" rating, raises price target from $42 to $43.
  • Vascular Solutions (NSDQ:VASC): Benchmark Co. reiterates "hold" rating, $17 price target; Canaccord Genuity reiterates "buy" rating, $20.50 price target

    • .

In case you missed it

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply